Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.01 CAD | -.--% | -.--% | -.--% |
Valuation
Fiscal Period: December | 2021 | 2022 |
---|---|---|
Capitalization 1 | 17.87 | 2.874 |
Enterprise Value (EV) 1 | 14.06 | 3.009 |
P/E ratio | -1.54 x | -0.59 x |
Yield | - | - |
Capitalization / Revenue | - | - |
EV / Revenue | - | - |
EV / EBITDA | - | -693,581 x |
EV / FCF | -3,823,542 x | -2,125,619 x |
FCF Yield | -0% | -0% |
Price to Book | 6.57 x | -1.81 x |
Nbr of stocks (in thousands) | 112,961 | 111,338 |
Reference price 2 | 0.1582 | 0.0258 |
Announcement Date | 3/2/22 | 4/28/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 |
---|---|---|---|
Net sales | - | - | - |
EBITDA | - | - | -4.338 |
EBIT 1 | -6.436 | -9.043 | -4.49 |
Operating Margin | - | - | - |
Earnings before Tax (EBT) 1 | -6.436 | -11.02 | -4.886 |
Net income 1 | -6.436 | -11.02 | -4.886 |
Net margin | - | - | - |
EPS | - | -0.1030 | -0.0437 |
Free Cash Flow | - | -3.678 | -1.415 |
FCF margin | - | - | - |
FCF Conversion (EBITDA) | - | - | - |
FCF Conversion (Net income) | - | - | - |
Dividend per Share | - | - | - |
Announcement Date | 2/17/21 | 3/2/22 | 4/28/23 |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA | - | - | - | - | - |
EBIT 1 | -4.755 | -2.95 | -2.596 | -1.884 | -1.813 |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -4.756 | -2.914 | -3.014 | -2.006 | -1.868 |
Net income 1 | -4.933 | -2.733 | -3.014 | -2.006 | -1.868 |
Net margin | - | - | - | - | - |
EPS | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 8/30/21 | 11/29/21 | 3/2/22 | 5/30/22 | 8/29/22 |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 |
---|---|---|---|
Net Debt 1 | - | - | 0.13 |
Net Cash position 1 | 0.27 | 3.81 | - |
Leverage (Debt/EBITDA) | - | - | -0.031 x |
Free Cash Flow | - | -3.68 | -1.42 |
ROE (net income / shareholders' equity) | - | -1,113% | -867% |
ROA (Net income/ Total Assets) | - | -263% | -128% |
Assets 1 | - | 4.187 | 3.829 |
Book Value Per Share 2 | -0.0100 | 0.0200 | -0.0100 |
Cash Flow per Share 2 | 0.0100 | 0 | 0 |
Capex | - | - | - |
Capex / Sales | - | - | - |
Announcement Date | 2/17/21 | 3/2/22 | 4/28/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-.--% | 965K | |
-3.17% | 102B | |
+1.62% | 96.09B | |
+2.13% | 22.28B | |
-16.20% | 21.4B | |
-9.35% | 18.14B | |
-39.98% | 17.02B | |
-14.18% | 16.09B | |
+5.82% | 13.83B | |
+33.77% | 11.97B |
- Stock Market
- Equities
- PSYB.H Stock
- Financials PsyBio Therapeutics Corp.